{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.41","value":"2.1"},{"groupId":"OG001","spread":"16.43","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"W7D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.58","value":"1.8"},{"groupId":"OG001","spread":"20.36","value":"4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"W13D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.30","value":"-0.2"},{"groupId":"OG001","spread":"23.07","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"W19D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.39","value":"1.5"},{"groupId":"OG001","spread":"22.18","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"120"}],"units":"Participants"}],"title":"Week 24 (D169)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"The Functional Assessment of Cancer Therapy - Anemia (FACT-An) questionnaire includes 47 items rating on a 5-point Likert scale from 0 (not at all) to 4 (very much) (so that 0 is considered worse quality of life and 4 is good response) on five primary subscales:\n\n* Physical well-being (sum of 7 items, score range from 0-28)\n* Social/Family well-being (sum of 7 items, score range from 0-28)\n* Emotional well-being (sum of 6 items, score range from 0-24)\n* Functional well-being (sum of 7 items, score range from 0-28)\n* Anemia-related symptoms (sum of 20 items, score range from 0-80)\n\nA total score for the FACT-An can be calculated by summing the five primary subscales with a score range from 0-188. Higher scores representing better quality of life. Baseline is defined as the last value on or before the first dose of study drug.","dispersionType":"Standard Deviation","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEAN","populationDescription":"All randomized participants who completed the Fact-An assessment at baseline and post-baseline assessment at the respective visit.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 on weeks 7,13,19, and 24.","title":"Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia Version 4 (FACT-An)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}